Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 13, 2026 07:05 ET | Source: Boehringer Ingelheim Limited

Boehringer Ingelheim advances potential first-in-class IL-11 inhibitor to Phase II Clinical Research in Idiopathic Pulmonary Fibrosis

Boehringer launches clinical trial exploring interleukin-11’s potential to go beyond slowing IPF and restore lung function.